Keep in mind that many of these patients will die of other comorbities, disseminated infection, malignancy, toximia, intracranial bleeding, acute renal failure and so on. Treating the DIC will help take that major contributer to mortality down but large numbers of very sick patients will need to be looked at to see the survival improvement we hope for by treating one of only several causes for demise. In the meantime if some as yet undefined advantage for the ART product emerges we in the deep(er) stuff. Flo, any idea when the Phase II data from Merrimack might be available? bp
Market Data 
Markets 
AI
